BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study of BMS-986012 in Subjects With Small Cell Lung Caner

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: BMS-986012
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2016-10-31

Last Posted Date: 2019-08-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7

Registration Number: NCT02949895

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Active, not recruiting

Conditions: Renal Cell Carcinoma

First Posted Date: 2016-10-21

Last Posted Date: 2022-05-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 499

Registration Number: NCT02940639

Locations: 🇩🇪
Local Institution, Jena, Germany

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Phase 2

Completed

Conditions: Advanced Gastric Cancer

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Biological: Relatlimab
Biological: BMS-986205
Drug: Rucaparib

First Posted Date: 2016-10-17

Last Posted Date: 2023-06-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 190

Registration Number: NCT02935634

Locations: 🇺🇸
Local Institution - 0001, Hackensack, New Jersey, United States
🇩🇪
Local Institution - 0043, Leipzig, Germany
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States

and more 25 locations

Study With Healthy Japanese and Non-Asian Participants With BMS-986231

Phase 1

Completed

Conditions: Heart Decompensation, Acute

Interventions: Drug: BMS-986231
Drug: BMS-986231 Placebo

First Posted Date: 2016-10-13

Last Posted Date: 2017-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 56

Registration Number: NCT02932969

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States

Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165
Drug: Placebo for BMS-986165

First Posted Date: 2016-10-13

Last Posted Date: 2020-11-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 268

Registration Number: NCT02931838

Locations: 🇺🇸
Renstar Medical Research, Ocala, Florida, United States
🇺🇸
NorthShore University Health System, Skokie, Illinois, United States
🇺🇸
Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States

and more 13 locations

Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Withdrawn

Conditions: Renal Cell Carcinoma

Interventions: Other: Non-Interventional

First Posted Date: 2016-10-10

Last Posted Date: 2017-07-17

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02928263

Locations: 🇺🇸
Bristol-Myers Squibb, Princeton, New Jersey, United States

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Phase 2

Completed

Conditions: Hodgkin Disease

Interventions: Biological: Nivolumab
Biological: bendamustine
Biological: brentuximab vedotin

First Posted Date: 2016-10-07

Last Posted Date: 2024-07-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 72

Registration Number: NCT02927769

Locations: 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸
Children'S Hospital & Research Center At Oakland, Oakland, California, United States
🇺🇸
Children'S Hospital Of Orange County, Orange, California, United States

and more 70 locations

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Phase 1

Completed

Conditions: Ischemic Stroke

Interventions: Drug: BMS-986141
Drug: Dilitazem

First Posted Date: 2016-10-04

Last Posted Date: 2016-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT02922452

Locations: 🇺🇸
PPD Development, Austin, Texas, United States

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy

Completed

Conditions: Anticoagulation

First Posted Date: 2016-10-03

Last Posted Date: 2018-08-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9914

Registration Number: NCT02921126

Locations: 🇮🇹
Local Institution, Ravenna, Italy

A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome

Phase 3

Completed

Conditions: Sjogrens Disease

Interventions: Biological: Abatacept
Other: Placebo

First Posted Date: 2016-09-26

Last Posted Date: 2020-08-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 250

Registration Number: NCT02915159

Locations: 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇮🇹
Ospedale Santa Maria Della Misericordia, Udine, Italy
🇸🇪
Local Institution, Uppsala, Sweden

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy